021-51111890
购物车（）
sales@molnova.cn
SRX3207
CAS No. 2254693-15-5
SRX3207 ( —— )
产品货号. M33816 CAS No. 2254693-15-5
SRX3207 是具有口服活性的、首创的 Syk/PI3K 双抑制剂，其对 Syk 和 PI3Kα 的 IC50 值分别为 10.7 nM 和 861 nM。SRX3207 缓解抗肿瘤免疫抑制。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥1093 | 有现货 |
|
| 10MG | ￥1606 | 有现货 |
|
| 25MG | ￥2502 | 有现货 |
|
| 50MG | ￥3302 | 有现货 |
|
| 100MG | ￥4401 | 有现货 |
|
| 200MG | ￥5931 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称SRX3207
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述SRX3207 是具有口服活性的、首创的 Syk/PI3K 双抑制剂，其对 Syk 和 PI3Kα 的 IC50 值分别为 10.7 nM 和 861 nM。SRX3207 缓解抗肿瘤免疫抑制。
-
产品描述SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression.
-
体外实验SRX3207 (10 μmol/L) is able to block p-AKT at concentration.SRX3207 has sufficient solubility in water (43 μmol/L).
-
体内实验SRX3207 (10 mg/kg, orally) increases antitumor immune response.Animal Model:LLC or B16 or B16-OVA or CT26 (1 × 105) cells were injected subcutaneously into syngeneic mice.Dosage:10 mg/kg.Administration:Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21.Result:Blocked phosphorylation of Syk at 348 site and Y525/526 site.Blocked immunosuppressive MΦ polarization.Blocked tumor growth and increased survival effectively.
-
同义词——
-
通路PI3K/Akt/mTOR signaling
-
靶点PI3K
-
受体PI3K | Syk
-
研究领域——
-
适应症——
化学信息
-
CAS Number2254693-15-5
-
分子量555.65
-
分子式C29H29N7O3S
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 5 mg/mL (9.00 mM; 超声助溶 )
-
SMILESCc1nn(cc1CN1CCC1)-c1ccnc(Nc2ccc(cc2)-c2csc3c2oc(cc3=O)N2CCOCC2)n1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Shweta Joshi, et al. Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020.
